For years I filed “have you tried mindfulness?” under the things people say when they have run out of anything useful to offer your back. It reads like a polite way of telling someone the pain is in their head. So when a trial of 451 people landed in JAMA Internal Medicine on June 29, claiming eight weeks of group meditation beat the usual American approach to chronic low back pain and kept beating it a year later, I went in hunting for the catch. There is one. It just isn’t the catch I expected, and it says more about the people who wrote the press release than the people who ran the study.
OPTIMUM ran out of Boston Medical Center, funded by the National Center for Complementary and Integrative Health, the arm of the NIH that pays for this kind of work through its pragmatic-trials network. The design is refreshingly ordinary: regular primary-care patients across Massachusetts, Pennsylvania, and North Carolina, average age 52, about 70 percent women, all living with the moderate, grinding back pain that steadily narrows what a day can hold. They were randomized close to evenly, 224 into the program and 227 into usual care. In American primary care that usual-care label tends to mean some rotating mix of anti-inflammatories, the occasional opioid, an injection or a scan, and a referral or two, which is context for the comparison rather than a protocol the trial dictated.
The program is where it gets specific. Eight weekly two-hour sessions over video, each one led by a trained mindfulness instructor sitting alongside an actual primary-care physician, and billed as a group medical visit so insurance has a box to tick. The technique is adapted from Mindfulness-Based Stress Reduction, but retooled so the pain itself becomes the stressor you practice on. Patients learn, in lead author Natalia Morone’s words, “real, repeatable skills for how to respond to pain differently.”
Here is where I stopped rolling my eyes. Meditation in this trial never pretends to switch the pain signal off. Whatever is driving the ache, a disc, an irritated nerve, a muscle that seizes when you twist wrong, the practice does not reach down and quiet it. What it works on sits upstream, in how the brain reads the signal. Pain isn’t a clean readout from the body; it’s closer to a prediction the brain assembles, weighting raw sensation with fear, attention, and the dread of what the ache might mean. Much of chronic pain lives in that weighting, in the brain’s volume control rather than the strings. So wait, why would sitting quietly with a sensation make it hurt less? Because you are training the volume knob, not the source, and that is probably why the benefit outlasted the classes: you don’t lose a skill the way you lose a drug’s blood level.
And it did outlast them. Eight weeks in, the meditation group had pulled ahead of usual care by 0.89 points on the 0-to-10 PEG scale that tracks pain and how much it interferes with life (p less than .001). At six months, the trial’s main checkpoint, the gap was 0.62 points (p = .002); at twelve months it was 0.74 (p less than .001). Look at each group on its own and the split is sharper: from baseline to a year out, the mindfulness group dropped 1.52 points while usual care fell 0.78, with 89 percent of everyone still enrolled at the finish. For a program with no addiction risk and no liver to keep an eye on, holding a benefit that long is good news, and it is the kind of evidence wellness skeptics keep insisting doesn’t exist.
So what’s the catch? It’s the one the press release tucked out of sight. Before a single patient enrolled, the researchers set their own bar for a difference a person could actually feel: at least 1 point of separation between the groups. The meditation arm never cleared it. The biggest gap it ever opened was that 0.89 at week eight, and it shrank from there. Statistically significant at every time point, yes. Clinically meaningful by the team’s own pre-registered definition, no. The Boston Medical Center announcement speaks warmly about significant improvements sustained at twelve months and never once mentions the threshold the study set for itself and missed. That is the reflex worth naming: when a publicly funded result comes back solid but modest, the machine sands off the modest and ships the win.
The honest reading beats both the hype and the dismissal. Usual care got better too over the year, some of it natural healing, some of it the attention of being in a study, some of it regression to the mean, and all of it narrowing the head-to-head gap even as the meditation group clearly improved on its own terms. So the true sentence is the boring one: people who learned these skills got meaningfully better, and they did somewhat better than people who got the standard runaround, by a margin that lands just under “you’d clearly feel the difference.” And it isn’t the only signal pointing this way. A 2024 telehealth mindfulness trial, also in JAMA Internal Medicine, improved function and pain interference across a range of chronic-pain conditions. The pattern keeps coming back small, durable, and unglamorous.
What bothers me isn’t the size of the effect. It’s that a small, drug-free benefit with a year-long tail gets treated as something to oversell instead of something to build on, while the same system reaches for opioids on this exact diagnosis without much hesitation. A modest tool that carries no pharmacology and still shows up a year later isn’t a letdown. It’s a category American medicine barely knows how to pay for.
If it were my back, I wouldn’t wait for the flawless trial or the press release’s blessing. I’d take eight weeks of free, low-risk skills over one more script I’d have to taper off later, and I’d walk in clear-eyed: the gain is lasting, drug-free, and smaller than the headline wants me to believe.
Sources
- JAMA Internal Medicine – Morone et al., OPTIMUM pragmatic RCT of mindfulness group medical visits for chronic low back pain (2026)
- Boston Medical Center / Mirage News – press release on the OPTIMUM results
- NIH Pragmatic Trials Collaboratory – OPTIMUM project and funding (NCCIH)
- ClinicalTrials.gov – NCT04129450, OPTIMUM trial registration
- JAMA Internal Medicine – telehealth mindfulness-based intervention for chronic pain (2024)